| 摘要 |
1. A pharmaceutical composition comprising a therapeutically effective amount of lymphotoxin-β receptor (LT-β-R) blocking agent and a pharmaceutically acceptable carrier. 2. The composition according to claim 1, wherein the LT-β-R blocking agent is selected from the group consisting of a soluble lymphotoxin-β receptor with an amino sequence SEQ.ID.NO.1, an antibody directed against lymphotoxin-β receptor (LT-β-R), an antibody directed against the surface lympfotoxin lygand (LT lygand). 3. The composition according to claim 2, wherein the soluble lymphotoxin-β receptor is a ligand binding domain having a ligand binding domain that can selectively bind to a surface LT ligand. 4. The composition according to claim 3, wherein the soluble lymphotoxin-β receptor further comprises a human immunoglobulin Fc domain. 5. The composition according to claim 2, wherein the LT-β-R blocking agent is a monoclonal antibody directed against LT-β receptor. 6. The composition according to claim 5, wherein the monoclinal antibody is mAb BDA8 directed against LT-β-R of a human. 7. The composition according to claim 2, wherein the LT-β-R blocking agent is a monoclonal antibody directed against LT-β receptor. 8. The composition according to claim 7, wherein, the antibody is directed against a subunit of the LT ligand. 9. The composition according to claim 7, wherein the monoclonal antibody is mAb B9 directed against LT-β of a human. 10. The composition according to claim 7, wherein the LT-β-R blocking agent is a monoclonal antibody directed against the LT ligand of a mouse. 11. A method for treating or reducing the advancement, severity or effects of an immunological disease in a mammal by inhibiting LT-β receptor signalling, wherein comprising administering to the mammal a pharmaceutical composition according to any claim 1 to 10. 12. The method for inhibiting the Th1 cell-mediated immune response signalling, wherein comprising administering to the mammal a pharmaceutical composition according to any claim 1 to 10. 13. The method according to claim 12, wherein the Th1 cell-mediated immune response contributes to cellular rejection of tissue in the mammal after the mammal receives a tissue graft. 14. The method according to claim 12, wherein the Th1 cell-mediated immune response contributes to organ rejection in the mammal after the mammal receives an organ transplant. 15. The method according to claim 15, wherein the Th1 cell-mediated immune response contributes to an autoimmune disorder in the mammal. 16. The method according to claim 15, wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis, insulin-dependent diabetes, sympathetic ophthalmia, uveitis and psoriasis. 17. The method according to claim 12, wherein the Th1 cell-mediated immune response is inhibited without inhibiting a Th2 cell-dependent immune response. 18. The method for treating inflammatory bowel disease in a mammal, wherein comprising administering to the mammal a pharmaceutical composition according to claim 4. |
